GBAF Logo
Global Banking & Finance Awards® 2026 Nominations open, free to enter Nominate now →
C

Celularity CELU · USD

Health Care · US listing · 🇺🇸 United States

Compare

0.76

-0.05%

Close of 9 Nov 2026, in USD

Search any instrument

Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.

About Celularity

From its filings with the US Securities and Exchange Commission

SEC filings

Celularity is based in Florham Park, New Jersey and is incorporated in Delaware. Its shares trade on Nasdaq under the ticker CELU. The SEC classifies its business as pharmaceutical preparations. In the fiscal year to 31 December 2025, it reported revenue of $26.6m and a net loss of $91.7m. At that date it held total assets of $107.3m and shareholders' equity of −$38.1m.

Read the filing on SEC.gov ↗

Company facts

Sector
Health Care
Industry
Biotechnology
Listed since
23 May 2019
Employees
225
Head office
170 PARK AVE, FLORHAM PARK, NJ, 07932
Incorporated in
DE
Classification
Pharmaceutical Preparations
Filer status
<br>Emerging growth company

Leadership

Pay as last reported

  • Dr. Robert HaririChairman of the Board, Chief Executive Officer, since 2021$848,959
  • Mr. Joseph DossantosInterim Chief Financial Officer
  • Mr. Stephen BrigidoPresident - Degenerative Disease
  • Mr. John HainesSenior Executive Vice President, Chief Administrative Officer, Corporate Secretary$517,006
  • Mr. Vincent LevienDirector
  • Dr. Peter DiamandisIndependent Director$353,001
  • Dr. Shiu Fei LingIndependent Director$348,751
  • Ms. Diane ParksIndependent Director$365,001
  • Mr. Carlos RamirezSenior Vice President - Investor Relations, since 2025

Environmental, social and governance

Scores out of 100, from our data supplier

ESG
Overall
17
Environment
4
Social
31
Governance
15
Carbon reduction policy
No
Human rights policy
No

SWOT analysis

AI-generated by our data supplier. Not written or checked by our editors.

AI-generated

Strengths

  • Celularity develops off-the-shelf placental-derived allogeneic cell therapies.
  • The company employs 225 full-time staff members.
  • It operates through three distinct business segments.

Weaknesses

  • The firm is classified as a clinical stage biotechnology company.
  • Its product candidates target cancer and infectious diseases.
  • The source description is treated as untrusted facts.

Opportunities

  • Therapies are in development for immune and degenerative diseases.
  • Product candidates include CAR T cells and natural killer cells.
  • MLASCs and exosomes are part of the therapeutic portfolio.

Threats

  • The company went public on May 23, 2019.
  • It is headquartered in Florham Park, New Jersey.
  • Specific indications include B-cell malignancies and infectious diseases.

Sources and methodology

Data on this tab
Our data supplier
Chart on the Overview
TradingView

Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.